

# MALARIA: PAST, PRESENT, AND FUTURE



**Laurence Slutsker, MD, MPH**  
*Associate Director for Science*  
**Center for Global Health**  
**Centers for Disease Control and Prevention**



# Overview

- ❑ **Malaria 101: Early history, biology, and epidemiology**
- ❑ **The first push for malaria eradication (1950–1970)**
- ❑ **Worsening of malaria control (1990s)**
- ❑ **New focus and scale-up success (2000–2010)**
  - **Is eradication possible now?**

# History: Major Scientific Milestones



Charles Alphonse Laveran  
Demonstrated **parasites**  
in patient's blood, 1880



Ronald Ross  
Discovered **Anopheles**  
**mosquito** as vector, 1897



Giovanni Batista Grassi  
Demonstrated **life cycle** from  
mosquito to man, 1898–1899

# Malaria Biology: The Human Malaria Parasites


## ❑ Intra-erythrocytic protozoan

## ❑ Human malaria: 4 major species

- *Plasmodium falciparum*
- *Plasmodium vivax*
- *Plasmodium ovale*
- *Plasmodium malariae*

## ❑ *P. falciparum*


- Potentially fatal severe disease
  - Red blood cell destruction → severe anemia
  - Sequestration in cerebral vessels → coma
- Multi-drug resistant





# Malaria Biology: Vectors of Human Malaria

- ❑ **>400 species of Anopheles mosquitoes found worldwide; ~50 transmit malaria**
- ❑ **Each species occupies distinct ecological niche**
- ❑ **Major African vectors tend to bite indoors and at night**
- ❑ **Biting and resting behavior affect transmission potential and control**



# Malaria Global Burden, 2008


- ❑ **~250 million clinical cases per year; 80% in Africa**
  - Children aged <5 years and pregnant women most affected
- ❑ **>800,000 deaths per year; >90% in Africa**
- ❑ **Disability from severe forms of the disease**
- ❑ **Annual economic burden**
  - GDP → 1.3% loss



GDP, Gross domestic product



# Prevalence of *P. falciparum* Malaria in Children Aged 2–10 Years



# Events Leading up to the Global Malaria Eradication Program

- ❑ **Early successes in mosquito control (Panama Canal)**
- ❑ **Effective interventions, chloroquine and DDT, became available after WWII**
- ❑ **Availability of good diagnosis with microscopy**
- ❑ **8<sup>th</sup> World Health Assembly launches Global Eradication Campaign (1955)**



# Eradication Strategies 1950–1970

- ❑ **“Magic bullet”**: DDT indoor residual spray (IRS)
- ❑ **Assumptions**
  - People stay indoors at night
  - *Anopheles* mosquito bites at night, rests indoors on house walls, and receives a toxic dose of DDT
- ❑ **Other major activities**
  - Antimalarial drug treatment: Patients, occasionally as mass treatment
  - Surveillance to detect and eliminate any reservoirs




# Eradication Successes

**Malaria was eliminated in 37 countries during 1950–1978**



**1950**



**1978**

# What Were the Problems?

<b>Technical</b>	Insecticide and drug resistance
<b>Logistics</b>	Supply chain failures Poor delivery of IRS
<b>Strategic</b>	Rigidity Lack of research Africa not included
<b>Financial</b>	Funds diverted elsewhere
<b>Sociocultural</b>	Lack of community buy-in and participation Decreasing acceptance of IRS

# Consequent Change in Strategy (1970s)

## ❑ 22<sup>nd</sup> World Health Assembly (1969)

- “Suspended” eradication campaign
- Goal became control to “Minimize the health damage by malaria”
  - Less ambitious
  - Strategy adapted to local context


## ❑ Shift from prevention with insecticides/DDT to antimalarial treatment

## ❑ Integrate activities into primary health care



# Worsening of Malaria Control (1990s)

- ❑ Decreased funding
- ❑ Intensification and spread of chloroquine resistance



# Renewed Optimism in the New Millennium

- ❑ **New partnerships**
- ❑ **New funding**
- ❑ **New political leadership in endemic countries**
- ❑ **New tools (drugs, bed nets)**



# A COMMITMENT TO MALARIA CONTROL AND PREVENTION: THE FIRST STEPS TOWARDS ELIMINATION



**John R. MacArthur, MD, MPH**  
*Chief, Program Implementation Unit*  
Division of Parasitic Diseases and Malaria  
Center for Global Health  
Centers for Disease Control and Prevention



# Overview

- ❑ **Roll Back Malaria and U.N. Millennium Development Goals**
- ❑ **President's Malaria Initiative (PMI)**
  - PMI under two presidents
  - Goals, targets, and funding
  - Focused interventions
  - CDC's role in PMI: Strategic information
- ❑ **Results achieved**
  - Significant reductions in malaria transmission



# Roll Back Malaria (RBM)

## □ Global partnership

- Launched in 1998
- WHO, UNICEF, UNDP, World Bank

## □ Global framework

- Coordination of activities
- Mobilization of resources
- Establishment of technical working groups
- Establishment of subregional networks

## □ Global Malaria Action Plan

- Launched September 25, 2008, by RBM partnership
- Scaling up for impact
- Sustaining control over time



# United Nations Millennium Development Goals (MDG)

[www.un.org/millenniumgoals](http://www.un.org/millenniumgoals)


- ❑ **Goal 4: Reduce child mortality**
- ❑ **Goal 5: Improve maternal health**
- ❑ **Goal 6: Combat HIV/AIDS, malaria, and other diseases**
  - Target 6c: Have halted by 2015 and begun to reverse the incidence of malaria and other major diseases
    - Incidence and death rates associated with malaria
    - Children under 5 sleeping under insecticide-treated bednets
    - Children under 5 with fever who are treated with appropriate anti-malarial drugs



**WE CAN**  
**END POVERTY**  
**2015** MILLENNIUM  
DEVELOPMENT  
GOALS



# International Financial Disbursements to Malaria Endemic




Source: Malaria funding and resource utilization: the first decade of Roll Back Malaria.  
<http://www.rbm.who.int/ProgressImpactSeries/docs/RBMMalariaFinancingReport-en.pdf>  
PMI, President's Malaria Initiative  
GF, Global Fund



# President's Malaria Initiative (PMI)

- ❑ On June 30, 2005, President Bush announced a new initiative to rapidly scale up malaria control interventions in high-burden countries in Africa
  - 5-year and \$1.2B investment
- ❑ Challenged other donors to increase their funding



- ❑ PMI is led by USAID and co-implemented with CDC

Source: S. Craighead/White House (12/14/06)



# PMI Goal and Targets

- ❑ **Goal: Reduce malaria-related mortality by 50% in 15 selected countries**
- ❑ **Targets: Achieve 85% coverage of vulnerable groups with 4 key interventions (~270 million residents)**



## Artemisinin-based combination therapies (ACTs)



## Indoor residual spraying (IRS) (where appropriate)



# ventions

## Insecticide-treated bed nets (ITNs)



## Intermittent preventive treatment in pregnancy (IPTp)



# PMI Funding Levels and Coverage

Year	Funding Level	No. Countries Covered
2006	\$30 M	3
2007	\$135 M	7
2008	\$300 M	15
2009	\$300 M	15
2010	\$500 M	15
<b>TOTAL</b>	<b>\$1,265 M</b>	





# PMI and the Global Health Initiative (GHI)

- ❑ **President Obama signals support for global health including malaria (September 2008)**
- ❑ **The White House launches Global Health Initiative**
  - U.S. Government will invest \$63 billion over 6 years
- ❑ **PMI is now a major component of GHI**

**"We will not be successful in our efforts to end deaths from AIDS, malaria, and tuberculosis unless we do more to improve health systems around the world, focus our efforts on child and maternal health, and ensure that best practices drive the funding for these programs."**

**—President Barack Obama, May 5, 2009**



# CDC's Mandate in PMI: Strategic Information

## ❑ U.S. Congress (through the Lantos-Hyde Act, 2008) charged CDC to take a leading role in strategic information

- Monitoring and evaluation
- Surveillance
- Operations research

### An Act

To authorize appropriations for fiscal years 2009 through 2013 to provide assistance to foreign countries to combat HIV/AIDS, tuberculosis, and malaria, and for other purposes.


*Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,*

#### SECTION 1. SHORT TITLE; TABLE OF CONTENTS.

(a) SHORT TITLE.—This Act may be cited as the “Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008”.


## ❑ CDC is advising the U.S. Malaria Coordinator on priorities for these activities and being a key implementer

# PMI Focus: 15 African Countries



**Angola  
Benin  
Ethiopia  
Ghana  
Kenya  
Liberia  
Madagascar  
Malawi  
Mali  
Mozambique  
Rwanda  
Senegal  
Tanzania  
Uganda  
Zambia**


# PMI Focus: Additional African Countries



**Nigeria and  
the Democratic Republic of Congo  
account for the 23%  
of the world's burden  
of the falciparum malaria**




# Proportion of Households with at Least 1 Insecticide-Treated Bed Net (ITN) from 2 Survey Points



Data source: Demographic Health Survey, <http://www.measuredhs.com>




# Proportion of Children Aged <5 Years Who Slept Under an ITN the Previous Night



Data source: Demographic Health Survey, <http://www.measuredhs.com>




# Zanzibar: Intervention Coverage and Malaria control



ITN, Insecticide-treated bed net  
 IRS, Indoor residual spraying  
 ACT, Artemisinin-based combination therapy



# Declines in All-Cause Mortality in Children Aged <5 Years, 7 PMI Countries, 2003–2010



Data source: Demographic Health Survey, <http://www.measuredhs.com>





# Resistance – A Lurking Threat

- ❑ Emergence of insecticide resistance in Africa
  - DDT, pyrethroids
- ❑ Emergence of artemisinin resistance in Southeast Asia
  - Thai-Cambodia border

TREPAR-988; No. of Pages 8

ARTICLE IN PRESS

Review

Cell  
PRESS

## Pyrethroid resistance in African anopheline mosquitoes: what are the implications for malaria control?

Hilary Ranson<sup>1</sup>, Raphael N'Guessan<sup>2,5</sup>, Jonathan Lines<sup>3</sup>, Nicolas Moiroux<sup>4,5</sup>, Zinga Nkuni<sup>3</sup> and Vincent Corbel<sup>4,5</sup>

<sup>1</sup> Vector Group, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, UK, L3 5QA  
<sup>2</sup> London School of Hygiene and Tropical Medicine, Keppel Street, London, UK, WC1E 7HT, UK  
<sup>3</sup> Global Malaria Programme (GMP), World Health Organization, 1211 Geneva 27, Switzerland  
<sup>4</sup> Institut de Recherche pour le Développement (IRD), RU016 « Caractérisation et Contrôle des Populations de Vecteurs », 01 BP 4414, Cotonou, Benin  
<sup>5</sup> Centre de Recherche Entomologique de Cotonou (CREC), Laboratoire National, Ministère de la Santé, Cotonou 06 BP 2604, Benin

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

## Artemisinin Resistance in *Plasmodium falciparum* Malaria

Arjen M. Dondorp, M.D., François Nosten, M.D., Poravuth Yi, M.D., Debashish Das, M.D., Aung Phae Phyo, M.D., Joel Tarning, Ph.D., Khin Maung Lwin, M.D., Frederic Ariey, M.D., Warunee Hanpithakpong, Ph.D., Sue J. Lee, Ph.D., Pascal Ringwald, M.D., Kamolrat Silamut, Ph.D., Mallika Imwong, Ph.D., Kesinee Chotivanich, Ph.D., Pharath Lim, M.D., Trent Herdman, Ph.D., Sen Sam An, Shunmay Yeung, Ph.D., Pratap Singhasivanon, M.D., Nicholas P.J. Day, D.M., Niklas Lindegardh, Ph.D., Duong Socheat, M.D., and Nicholas J. White, F.R.S.

# Summary: Results Achieved

## ❑ Significant reductions in all-cause mortality

➤ Tanzania	19%
➤ Madagascar	22%
➤ Ghana	28%
➤ Zambia	29%
➤ Senegal	30%
➤ Rwanda	32%
➤ Kenya	36%

❑ **Massive scale-up of control interventions has been followed by substantial decreases in all-cause mortality in children aged <5 years**

❑ **Initiative-wide impact assessment is under way**

# CDC's SCIENTIFIC EVIDENCE BASE FOR SCALE-UP AND POSITIONING FOR MALARIA ELIMINATION



**S. Patrick Kachur, MD, MPH**  
*Chief, Strategic and Applied Sciences Unit*  
**Division of Parasitic Diseases and Malaria**  
**Center for Global Health**  
**Centers for Disease Control and Prevention**

# Overview

- 1. Scientific evidence: Basis for current interventions**
- 2. Global Malaria Eradication Research Agenda**
- 3. CDC operational research priorities, 2010**





# 1. Scientific Evidence: Basis for Current Malaria Interventions

**Artemisinin-based  
combination therapies (ACTs)**



**Insecticide-treated  
bed nets (ITNs)**



**Indoor residual spraying  
(IRS) (where appropriate)**



**Intermittent preventive  
treatment in pregnancy (IPTp)**



# Efficacy of ITNs on All-Cause Child Mortality from 4 Randomized Controlled Trials in Africa

Study or subgroup	Treated nets N	Control N	log [Relative rate] (SE)	Relative rate IV,Fixed,95% CI	Relative rate IV,Fixed,95% CI
I Controls with no nets					
Kenya (Nevill)	11596	11439	-0.3425 (0.157)		0.71 [ 0.52, 0.97 ]
Ghana (Binka)	18457	18054	-0.1985 (0.093)		0.82 [ 0.68, 0.98 ]
Burkina Faso (Habluetzel)	14773	14118	-0.1508 (0.1139)		0.86 [ 0.69, 1.08 ]
Kenya (Phillips-Howard)	17833	18099	-0.1744 (0.058)		0.84 [ 0.75, 0.94 ]
<b>Subtotal (95% CI)</b>					<b>0.83 [ 0.76, 0.90 ]</b>

**17% protective efficacy against child mortality before age of 5 years**  
**Could save 5.5 lives for every 1,000 children protected**

ITN, Insecticide-treated bed net

C Lengeler. Insecticide-treated bed nets and curtains for preventing malaria. Cochrane Database of Systematic Reviews 2004, Issue 2.



# Additional Lessons from the KEMRI/CDC ITN Trial and Follow-up Studies

- ❑ **People without nets experienced the same benefit if they lived within 300 meters of net users – reduction in**
  - Parasite infection (odds ratio=0.59)
  - Malaria illness (odds ratio=0.52)
  - Anemia (odds ratio=0.53)
  - Child mortality (hazard ratio=0.72)

*Am. J. Trop. Med. Hyg.*, 68(Suppl 4), 2003, pp. 121-127  
Copyright © 2003 by The American Society of Tropical Medicine and Hygiene

## COMMUNITY-WIDE EFFECTS OF PERMETHRIN-TREATED BED NETS ON CHILD MORTALITY AND MALARIA MORBIDITY IN WESTERN KENYA

WILLIAM A. HAWLEY, PENELOPE A. PHILLIPS-HOWARD, FEIKO O. TER KUILE, DIANNE J. TERLOUW, JOHN M. VULULE, MAURICE OMBOK, BERNARD L. NAHLEN, JOHN E. GIMNIG, SIMON K. KARIUKI, MARGARETTE S. KOLCZAK, AND ALLEN W. HIGHTOWER

*Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; Centre for Vector Biology and Control Research, Kenya Medical Research Institute, Kisumu, Kenya; Department of Infectious Diseases, Tropical Medicine & AIDS, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands*

**Abstract.** Spatial analyses of the effect of insecticide (permethrin)-treated bed nets (ITNs) on nearby households both with and without ITNs was performed in the context of a large-scale, group-randomized, controlled mortality trial in Asembo, western Kenya. Results illustrate a protective effect of ITNs on compounds lacking ITNs located within 300 meters of compounds with ITNs for child mortality, moderate anemia, high-density parasitemia, and hemoglobin levels. This community effect on nearby compounds without nets is approximately as strong as the effect observed within villages with ITNs. This implies that in areas with intense malaria transmission with high ITN coverage, the primary effect of insecticide-treated nets is via area-wide effects on the mosquito population and not, as commonly supposed, by simple imposition of a physical barrier protecting individuals from biting. The strength of the community effect depended upon the proportion of nearby compounds with treated nets. To maximize their public health impact, high coverage with treated nets is essential.



# Additional Lessons from the KEMRI/CDC ITN Trial and Follow-up Studies

- ❑ **Survival benefit lasted beyond 6 years**
- ❑ **Mortality rates**
  - Infants: 113/1,000
  - Children 1–5 years old: 28/1,000



## Sustainability of Reductions in Malaria Transmission and Infant Mortality in Western Kenya With Use of Insecticide-Treated Bednets 4 to 6 Years of Follow-up

Kim A. Lindblade, PhD

Thomas P. Eisele, PhD

John E. Gimnig, PhD

Jane A. Alaii, PhD

Frank Odhiambo, MPH

Feiko O. ter Kuile, MD, PhD

William A. Hawley, PhD

Kathleen A. Wannemuehler, MS

Penelope A. Phillips-Howard, PhD

Daniel H. Rosen, PhD

Bernard L. Nahlen, MD

Dianne J. Terlouw, MD, PhD

Kubaje Adazu, PhD

John M. Vulule, PhD

Laurence Slutsker, MD, MPH

Nations Development Program, the United Nations Children's Fund, and the World Bank, aims to halve malaria mortality by 2010 through implementation of 4 key technical strategies: insecticide-treated bednets, improved case

See also Patient Page.

**Context** Insecticide-treated bednets reduce malaria transmission and child morbidity and mortality in short-term trials, but this impact may not be sustainable. Previous investigators have suggested that bednet use might paradoxically increase mortality in older children through delayed acquisition of immunity to malaria.

**Objectives** To determine whether adherence to and public health benefits of insecticide-treated bednets can be sustained over time and whether bednet use during infancy increases all-cause mortality rates in older children in an area of intense perennial malaria transmission.

**Design and Setting** A community randomized controlled trial in western Kenya (phase 1: January 1997 to February 2000) followed by continued surveillance of adherence, entomologic parameters, morbidity indicators, and all-cause mortality (phase 2: April 1999 to February 2002), and extended demographic monitoring (January to December 2002).

**Participants** A total of 130 000 residents of 221 villages in Asembo and Gem were randomized to receive insecticide-treated bednets at the start of phase 1 (111 villages) or phase 2 (110 villages).

**Main Outcome Measures** Proportion of children younger than 5 years using insecticide-treated bednets, mean number of *Anopheles* mosquitoes per house, and all-cause mortality rates.

**Results** Adherence to bednet use in children younger than 5 years increased from 65.9% (JAMA. 2004;291:2571-2580) www.jama.com

**Author Affiliations:** Division of Parasitic Diseases, Centers for Disease Control and Prevention, Atlanta, Ga (Drs Lindblade, Gimnig, ter Kuile, Hawley, Phillips-Howard, Rosen, Nahlen, Terlouw, and Slutsker, and Ms Wannemuehler), Department of International Health and Development, Tulane School of Public Health and Tropical Medicine, New Orleans, La (Dr Eisele), Centre for Vector Biology and Control Research, Kenya Medical Research Institute, Kisumu (Drs Alaii and Vulule, and Mr Odhiambo); and

CDC/Kenya, Kenya Medical Research Institute, Nairobi (Dr Adazu). Drs ter Kuile and Terlouw are now with Liverpool School of Tropical Medicine, Liverpool, England. Dr Nahlen is now with Roll Back Malaria, World Health Organization, Geneva, Switzerland.

**Corresponding Author:** Kim A. Lindblade, PhD, Division of Parasitic Diseases, Centers for Disease Control and Prevention, 4770 Buford Hwy, MS F-22, Atlanta, GA 30333 (klindblade@kisan.mimcom.net).

©2004 American Medical Association. All rights reserved.

(Reprinted) JAMA, June 2, 2004—Vol 291, No. 21 2571



# Additional Lessons from the KEMRI/ CDC ITN Trial and Follow-up Studies

- Providing nets to 65% of older children and adults would protect even children without nets



Adam Nadel, Freelance

OPEN ACCESS Freely available online

PLOS MEDICINE

## Preventing Childhood Malaria in Africa by Protecting Adults from Mosquitoes with Insecticide-Treated Nets

Gerry F. Killeen<sup>1,2\*</sup>, Tom A. Smith<sup>3</sup>, Heather M. Ferguson<sup>1,4,5</sup>, Hassan Mshinda<sup>1</sup>, Salim Abdulla<sup>1</sup>, Christian Lengeler<sup>3</sup>, Steven P. Kachur<sup>1,6</sup>

**1** Ifakara Health Research and Development Centre, Ifakara, Morogoro, United Republic of Tanzania, **2** Department of Biological and Biomedical Sciences, University of Durham, Durham, United Kingdom, **3** Department of Public Health and Epidemiology, Swiss Tropical Institute, Basel, Switzerland, **4** Division of Infection and Immunity, Glasgow University, Glasgow, United Kingdom, **5** Division of Environmental and Evolutionary Biology, Glasgow University, Glasgow, United Kingdom, **6** United States Public Health Service Commissioned Corps and Malaria Branch, Division of Parasitic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

# Policy Impact of the KEMRI/ CDC ITN Trial and Follow-up Studies

**Established the evidence-base for widespread  
scale-up and universal coverage**

**FROM EVIDENCE TO POLICY**



**Continued progress in scale-up and elimination  
will require improved tools  
for malaria control and surveillance**

- Scale-up: Aims to reduce morbidity and mortality**
- Elimination: Aims to reduce transmission**
  - Basic reproduction number  $<1.0$**

## 2. Global Malaria Eradication Research Agenda

### □ **New tools and systems to accommodate**

- Drugs
- Vaccines
- Diagnostics
- Insecticides

### □ **Strategies to manage resistance to antimalarial drugs and insecticides for public health**

- Combination treatments
- Combined delivery systems
- Rotational or mosaic deployment



maIERA  
Malaria Eradication Research Agenda

# Global Malaria Eradication Research Agenda



- ❑ **Alternative vector interventions**
  - ITNs and spraying work against mosquitoes indoors
  - Some mosquitoes feed and rest outdoors
    - Larviciding
    - Spatial repellents, baited traps
- ❑ **Drug interventions for reducing transmission**
  - Mass screen and treatment
  - Transmission-blocking agents
- ❑ **Surveillance: Detecting and responding to local transmission**

ITN, Insecticide-treated bed net





# 3. CDC Operational Research Priorities in 2010

## From Scale-up To Elimination

- ❑ **Optimize current malaria control interventions**
- ❑ **Establish role for new and revisited interventions**
  - Research and development
  - Clinical and field trials of new interventions
- ❑ **Integration with other initiatives**

# Research and Development: Field-Ready, High-Sensitivity Test for Malaria

- ❑ **WHO now calls for universal access to malaria diagnosis and treatment for every case of suspected malaria**
- ❑ **Diagnostic confirmation**
  - Minimize the overuse of treatments
  - Improves detection and treatment of other causes of illness
  - Forms the basis of a reliable system for monitoring malaria and malaria control



Light microscopy



Rapid antigen detection

# Research and Development: Field-Ready, High-Sensitivity Test for Malaria

- ❑ **As endemic countries approach elimination, highly sensitive tests become more critical**
- ❑ **Current diagnostic formats will improve management of malaria illness**
- ❑ **Elimination may rest on molecular assays**
  - Available only in reference laboratories far from remote areas




Molecular assays

# Research and Development: Field-Ready, High-Sensitivity Test for Malaria

- ❑ **CDC and University of Georgia**
- ❑ **Novel system for molecular diagnosis**
- ❑ **Real-time fluorescence loop-mediated amplification: Real LAMP**
  - Detection of malaria parasites at very low numbers
  - Without access to reference laboratory staffing and equipment
  - Validation of the first generation prototype on specimens from Tanzania completed

Real-LAMP





# Clinical and Field Trials of New Interventions

## □ Phase III malaria vaccine trial in Kenya

- First candidate vaccine to reach this stage of development
- One of 11 sites in 9 countries
- Could reduce clinical malaria by up to 35%, severe malaria by 49%



PL Alonso, *et al.* (2004). Efficacy of the RTS,S/AS02A vaccine against *Plasmodium falciparum* infection and disease in young African children: randomised controlled trial. *Lancet* 364(9443):1411-20.



# Clinical and Field Trials of New Interventions

## □ When will we have a vaccine that can eliminate malaria?

- Current vaccine within 18–24 months
- Will reduce illness burden, not transmission
- Hundreds of other candidates in development
- Millennia of co-evolution confound development



# Clinical and Field Trials of New Interventions

## ❑ Combined impact of ITNs with indoor residual spraying

- Western Kenya (2008–2010)
- Northern Ghana (starting 2011)



## ❑ Combined impact of ITNs with insecticide-treated durable wall liners


- Lakeside Malawi (starting 2011)



# Integration Opportunities

## From Scale-up To Elimination

- ❑ **Community-based control/ elimination**
- ❑ **Integrated case management interventions**
- ❑ **Integrated vector control**
- ❑ **Integrated surveillance, monitoring and evaluation**



# From Scale-Up to Elimination: the Role of Partnership

## ❑ Creative partnerships within the U.S. government

- Within Department of Health and Human Services
- With U.S. government partners

## ❑ Partnerships beyond our system

